BioAegis Therapeutics Overview
- Year Founded
-
2011
- Status
-
Private
- Employees
-
12
- Latest Deal Type
-
Grant
- Latest Deal Amount
-
$20M
- Investors
-
3
BioAegis Therapeutics General Information
Description
Operator of a clinical-stage drug development company intended to facilitate the treatment of inflammation and infectious diseases. The company specializes in the research of drugs to restore plasma gelsolin an innate immunity that provides an immunotherapeutic approach to fighting pathogens, enabling patients suffering from severe conditions with high unmet medical needs to receive biomarker-directed treatments across a range of indications.
Contact Information
Website
www.bioaegistherapeutics.comCorporate Office
- Commercialization Center for Innovative Technology
- 685 US Route 1
- North Brunswick, NJ 08902
- United States
Corporate Office
- Commercialization Center for Innovative Technology
- 685 US Route 1
- North Brunswick, NJ 08902
- United States
BioAegis Therapeutics Timeline
BioAegis Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 10. Grant | 16-Oct-2023 | $20M | Completed | Clinical Trials - Phase 2 | ||
| 9. Later Stage VC | 22-Mar-2022 | Completed | Clinical Trials - Phase 2 | |||
| 8. Later Stage VC (Series C) | 31-Dec-2021 | Completed | Clinical Trials - Phase 2 | |||
| 7. Later Stage VC | 07-Oct-2020 | Completed | Clinical Trials - Phase 2 | |||
| 6. Debt - PPP | 28-Apr-2020 | Completed | Clinical Trials - Phase 2 | |||
| 5. Later Stage VC (Series B) | 01-Aug-2018 | Completed | Clinical Trials - General | |||
| 4. Grant | 09-Jul-2016 | Completed | Clinical Trials - General | |||
| 3. Later Stage VC | 11-Mar-2016 | Completed | Startup | |||
| 2. Early Stage VC (Series A) | 01-Jan-2015 | $8.04M | $11M | Completed | Startup | |
| 1. Angel (individual) | 08-Feb-2013 | $3M | $3M | Completed | Startup |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
Opportunity Score
Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.
Exit Type
Evaluates the likelihood of a successful exit for investors, and the most likely exit type.
BioAegis Therapeutics Comparisons
Industry
Financing
Details
BioAegis Therapeutics Competitors (14)
One of BioAegis Therapeutics’s 14 competitors is Asceneuron, a Venture Capital-Backed company based in Lausanne, Switzerland.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Asceneuron | Venture Capital-Backed | Lausanne, Switzerland | ||||
| Endogena Therapeutics | Venture Capital-Backed | Zurich, Switzerland | ||||
| Alkahest | Formerly VC-backed | San Carlos, CA | ||||
| AviadoBio | Venture Capital-Backed | London, United Kingdom | ||||
| Inflammasome Therapeutics | Venture Capital-Backed | Newton, MA |
BioAegis Therapeutics Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
BioAegis Therapeutics Patents
BioAegis Therapeutics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| AU-2021347408-A1 | Compositions and methods for identifying and treating microparticle-associated diseases and conditions | Pending | 23-Sep-2020 | ||
| AU-2021347408-A9 | Compositions and methods for identifying and treating microparticle-associated diseases and conditions | Pending | 23-Sep-2020 | ||
| EP-4204818-A1 | Compositions and methods for identifying and treating microparticle-associated diseases and conditions | Pending | 23-Sep-2020 | ||
| CA-3196026-A1 | Compositions and methods for identifying and treating microparticle-associated diseases and conditions | Pending | 23-Sep-2020 | ||
| US-20230398176-A1 | Compositions and methods for identifying and treating microparticle-associated diseases and conditions | Pending | 23-Sep-2020 | A61K38/16 |
BioAegis Therapeutics Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
BioAegis Therapeutics Investors (3)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Biomedical Advanced Research and Development Authority | Government | |||
| European Investment Fund | Fund of Funds | Minority | ||
| National Institute Of Allergy and Infectious Diseases | Government |
BioAegis Therapeutics FAQs
-
When was BioAegis Therapeutics founded?
BioAegis Therapeutics was founded in 2011.
-
Where is BioAegis Therapeutics headquartered?
BioAegis Therapeutics is headquartered in North Brunswick, NJ.
-
What is the size of BioAegis Therapeutics?
BioAegis Therapeutics has 12 total employees.
-
What industry is BioAegis Therapeutics in?
BioAegis Therapeutics’s primary industry is Drug Discovery.
-
Is BioAegis Therapeutics a private or public company?
BioAegis Therapeutics is a Private company.
-
What is BioAegis Therapeutics’s current revenue?
The current revenue for BioAegis Therapeutics is .
-
How much funding has BioAegis Therapeutics raised over time?
BioAegis Therapeutics has raised $56.7M.
-
Who are BioAegis Therapeutics’s investors?
Biomedical Advanced Research and Development Authority, European Investment Fund, and National Institute Of Allergy and Infectious Diseases have invested in BioAegis Therapeutics.
-
Who are BioAegis Therapeutics’s competitors?
Asceneuron, Endogena Therapeutics, Alkahest, AviadoBio, and Inflammasome Therapeutics are some of the 14 competitors of BioAegis Therapeutics.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »
